FDA nears decision authorizing COVID-19 treatment with convalescent plasma

Antibody-rich blood plasma would be one of the first coronavirus treatments to receive approval, which could pave way for wider use

By Amy Dockser Marcus & Thomas M. Burton, The Wall Street Journal

The Food and Drug Administration is nearing a decision to authorize emergency use of antibody-rich blood plasma from recovered Covid-19 patients for treating those infected with the coronavirus, people familiar with the matter said.

The authorization could come as soon as next week, according to the people, though the agency could also decide to delay a decision. Read more …